$1.03 Billion in Sales Expected for DENTSPLY SIRONA Inc (NASDAQ:XRAY) This Quarter

Wall Street analysts predict that DENTSPLY SIRONA Inc (NASDAQ:XRAY) will announce $1.03 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for DENTSPLY SIRONA’s earnings, with the lowest sales estimate coming in at $1.02 billion and the highest estimate coming in at $1.05 billion. DENTSPLY SIRONA reported sales of $1.04 billion during the same quarter last year, which would suggest a negative year over year growth rate of 1%. The company is expected to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that DENTSPLY SIRONA will report full-year sales of $4.01 billion for the current financial year, with estimates ranging from $3.99 billion to $4.02 billion. For the next financial year, analysts anticipate that the firm will post sales of $4.14 billion, with estimates ranging from $4.09 billion to $4.17 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow DENTSPLY SIRONA.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 EPS for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.10. The firm had revenue of $946.20 million during the quarter, compared to analyst estimates of $925.13 million. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The company’s revenue was down 1.0% on a year-over-year basis. During the same period last year, the company earned $0.45 earnings per share.

A number of analysts recently commented on XRAY shares. Bank of America started coverage on DENTSPLY SIRONA in a research report on Monday, March 18th. They issued a “buy” rating and a $57.00 price objective for the company. ValuEngine upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Saturday, March 9th. BidaskClub upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Finally, HC Wainwright set a $49.00 target price on DENTSPLY SIRONA and gave the stock a “hold” rating in a research report on Friday, April 5th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $53.62.

Shares of XRAY stock opened at $57.63 on Friday. The stock has a 50-day moving average price of $55.58. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.35 and a current ratio of 2.06. The firm has a market capitalization of $13.54 billion, a price-to-earnings ratio of 28.67, a price-to-earnings-growth ratio of 2.15 and a beta of 0.96. DENTSPLY SIRONA has a 12 month low of $33.93 and a 12 month high of $59.40.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Stockholders of record on Friday, June 28th will be given a dividend of $0.0875 per share. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. This represents a $0.35 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend is Thursday, June 27th. DENTSPLY SIRONA’s payout ratio is presently 17.41%.

In other DENTSPLY SIRONA news, Director Betsy D. Holden acquired 2,720 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were acquired at an average price of $55.31 per share, for a total transaction of $150,443.20. Following the acquisition, the director now directly owns 9,224 shares of the company’s stock, valued at approximately $510,179.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Maureen J. Macinnis sold 15,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $56.06, for a total value of $840,900.00. Following the transaction, the senior vice president now owns 25,360 shares in the company, valued at approximately $1,421,681.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 26,417 shares of company stock valued at $1,425,395 and have sold 138,922 shares valued at $7,631,805. 0.62% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in DENTSPLY SIRONA by 1.8% in the 4th quarter. BlackRock Inc. now owns 14,334,332 shares of the medical instruments supplier’s stock valued at $533,380,000 after acquiring an additional 257,243 shares in the last quarter. Veritas Asset Management LLP lifted its stake in DENTSPLY SIRONA by 0.6% in the 1st quarter. Veritas Asset Management LLP now owns 13,549,320 shares of the medical instruments supplier’s stock valued at $671,911,000 after acquiring an additional 76,545 shares in the last quarter. Geode Capital Management LLC lifted its stake in DENTSPLY SIRONA by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 2,997,698 shares of the medical instruments supplier’s stock valued at $111,355,000 after acquiring an additional 185,780 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in DENTSPLY SIRONA by 2.9% in the 1st quarter. Champlain Investment Partners LLC now owns 2,890,795 shares of the medical instruments supplier’s stock valued at $143,355,000 after acquiring an additional 80,555 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in DENTSPLY SIRONA by 0.8% in the 1st quarter. Northern Trust Corp now owns 2,602,651 shares of the medical instruments supplier’s stock valued at $129,065,000 after acquiring an additional 21,321 shares in the last quarter. Institutional investors and hedge funds own 91.66% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

See Also: What is the Quick Ratio?

Get a free copy of the Zacks research report on DENTSPLY SIRONA (XRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.